TABLE 2.

Reported pharmacokinetic properties of top hits. All studies were performed on humans unless otherwise indicated.

	Indication	C max (ng/ml)	MW (g/mol)	C max (uM)	EC 50 (uM)	Elimination T 1/2	Dosing Regimen	References
Thiostrepton	Topical antibiotic, vetrinary		1,664		4.0
Oxytocin	Modify social behavior (expeirmental)	0.005	1,007	0.005	4.2	>1 h	Intranasal Single dose, 44 ug	Gossen et al (2012)
	Induction of labor	0.005	1,007	0.005	4.2	>>1 h	IV infusion 6.7 ng/min	Leake et al. (1980)
Nilotinib	Kinase inhibitor, Cancer treatment	1,360	529	2.57	4.2	16 h	Oral BID 300 mg	Tian et al. (2018)
Hydroxycamptothecin (in Rats)		15,930	364.4	43.7	7.3	428 min	RATS 10 mg/kg IV	Zhang (1998)
Selamectin (in Dogs)		86.5	770	0.11	8.5	266 h	DOGS topical 24 mg/kg	Sarasola et al. (2002)
		7,630	770	9.9	8.5	45.7 h	DOGS oral 24 mg/kg	Sarasola et al. (2002)
Picropodophyllin (PPP)	IGF inhibitror, Cancer treatment (aka AXL1717)	207–1,035	414	0.5–2.5	10.0	2 h	Oral 390 or 520 mg BID	Ekman et al. (2016)
Docetaxel	Microtubule inhibitor, Cancer treatment	933	808	1.23	10.3	25.4 h	IV infusion 30–36 mg/m2	Gustafson et al. (2003)
Doramectin	Antiparasitic, vetrinary	12.2	899	0.0135	12.8	10 days	CATTLE topical 500 ug/kg	Gayrard et al. (1999)
Anidulafungin	Antifungal	2,500	1,140	2.2	13.1	27 h	IV infusion 100 mg	Wasmann et al. (2018)
Estradiol Benzoate	Contraceptive	0.75	376	0.002	17.3	3 days	IM injection, 5 mg	Oriowo et al. (1980)